Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Moderna’s COVID Vaccine Sheds Negative Comparison On Myocarditis With BLA Approval

Executive Summary

Unlike the current EUA fact sheet, Spikevax’s approved labeling does not state that the vaccine may pose an increased risk of myocarditis ‘relative to other authorized or approved mRNA COVID-19 vaccines.’ Approval brings Moderna a priority review voucher, as did Comirnaty’s approval for BLA sponsor BioNTech.

You may also be interested in...



All Myocarditis, Pericarditis Cases With COVID-19 Vaccines Now Must Be Reported To VAERS

The change to three vaccine emergency use authorizations was made quietly, most recently for the Novavax vaccine.

Novavax EUA Justified By US FDA With Claims Of COVID Vaccine Supply Constraints

The agency also includes a myocarditis warning in the fact sheet for the first protein-based COVID-19 vaccine to reach the US market.

Moderna Looks To Catch Up In COVID-19 For Kids, While Still Branching Out In Other Areas

The company hopes to expand Spikevax’s reach beyond the current approved population while also looking to take the lead in mRNA vaccines in other diseases.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel